23821-37-6

Basic information

• Product Name: 3-OXO-3-PYRIDIN-4-YL-PROPIONITRILE
• Synonyms: 3-OXO-3-PYRIDIN-4-YLPROPANENITRILE;3-OXO-3-PYRIDIN-4-YL-PROPIONITRILE;3-OXO-4-PYRIDIN-3-YL-PROPIONITRILE;4-(2-Cyanoacetyl)pyridine;3-Oxo-3-(4-pyridinyl)propanenitrile;Beta-oxo-4-pyridinepropanenitrile;3-oxo-3-(yridine-4-yl)propanenitrile;b-oxo-4-Pyridinepropanenitrile
• CAS NO: 23821-37-6
• Molecular Formula: C₈H₆N₂O
• Molecular Weight: 146.15
• Product Categories: Pyridines;API intermediates
• Mol File: 23821-37-6.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 335.3 °C at 760 mmHg
• Flash Point: 156.6 °C
• Appearance: /
• Density: 1.177 g/cm³
• Vapor Pressure: 0.000121mmHg at 25°C
• Refractive Index: 1.539
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 6.29±0.10(Predicted)
• CAS DataBase Reference: 3-OXO-3-PYRIDIN-4-YL-PROPIONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-OXO-3-PYRIDIN-4-YL-PROPIONITRILE(23821-37-6)
• EPA Substance Registry System: 3-OXO-3-PYRIDIN-4-YL-PROPIONITRILE(23821-37-6)

Safety Data

• Hazard Codes: T,Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• Hazardous Substances Data: 23821-37-6(Hazardous Substances Data)

Usage

General Description

3-OXO-3-PYRIDIN-4-YL-PROPIONITRILE, also known as DHPN, is a chemical compound with the molecular formula C8H6N2O. It is a yellow crystalline substance commonly used in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. DHPN is a versatile intermediate with high reactivity, making it a valuable building block in chemical synthesis. It is known for its strong nitrile function and pyridine ring, which contribute to its diverse applications in the field of organic chemistry. DHPN is also used as a starting material in the preparation of various heterocyclic compounds, making it an important compound in the pharmaceutical and chemical industries.

InChI:InChI=1/C8H6N2O/c9-4-1-8(11)7-2-5-10-6-3-7/h2-3,5-6H,1H2

Upstream product

• 1570-45-2 isonicotinic acid ethylester 
• 75-05-8 acetonitrile 
• 104-12-1 p-chlorphenylisocyanate 
• 2459-09-8 4-pyridinecarboxylic acid, methyl ester 

Downstream Products

• 1240522-06-8 C₃₃H₂₉N₅O₃ 
• 1240522-08-0 (S)-N-(1-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-phenyl-2-(thiazol-4-ylmethylamino)propanamide 
• 1401219-43-9 N-(3-(pyridin-4-yl)-1-(p-tolyl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 6043-00-1 1-phenyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine 
• 676563-19-2 (S)-3-hydroxy-3-(pyridin-4-yl)propanenitrile 
• 1372452-66-8 (R)-3-hydroxy-3-(pyridin-4-yl)propanenitrile 
• 38965-47-8 1-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine 
• 1442476-47-2 C₂₃H₂₁F₃N₆OS 
• 1442476-45-0 (S)-N-(1-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-yl)-3-phenyl-2-((thiazol-5-ylmethyl)amino)propanamide 
• 1240522-05-7 (S)-tert-butyl 1-(1-methyl-3-(pyridin-4-yl)-1H-pyrazol-5-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate 

Relevant articles and documents

SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS

This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological diseases.

5- OR 7-AZAINDAZOLES AS BETA-LACTAMASE INHIBITORS

The present invention relates to β-lactamase inhibitors having the following general formula (I): wherein R1-R4 and X1-X2 are defined in the specification, pharmaceutical composition thereof, and use thereof for the treatment of a bacterial infection, alone or in combination with β-lactam antibiotics and/or other antibiotics and/or other β-lactamase inhibitors.

NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS

The present invention covers substituted Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.